Galmed Pharma (GLMD) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures dip after AI rout, telecoms slide
- Brent crude hits more than five-month high on concern over Middle East escalation
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Primis Financial (FRST) Misses Q3 EPS by 7c
- American Express raises annual guidance amid strong billings, customer acquisition
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
